The role of RAS oncogenes in controlling epithelial mechanics

被引:16
|
作者
Nyga, Agata [1 ]
Ganguli, Sushila [2 ]
Matthews, Helen K. [3 ]
Baum, Buzz [1 ,2 ,4 ]
机构
[1] Med Res Council Lab Mol Biol, Cambridge CB2 0QH, England
[2] UCL, Med Res Council Lab Mol Cell Biol, London WC1E 6BT, England
[3] Univ Sheffield, Sch Biosci, Western Bank, Sheffield S10 2TN, England
[4] UCL, Inst Phys Living Syst, London WC1E 6BT, England
基金
英国医学研究理事会; 英国惠康基金;
关键词
FOCAL ADHESION KINASE; SERINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; SIGNALING PATHWAYS; HIPPO PATHWAY; ACTIVATION; PAXILLIN; GROWTH; TRANSFORMATION; MYOSIN;
D O I
10.1016/j.tcb.2022.09.002
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mutations in RAS are key oncogenic drivers and therapeutic targets. Oncogenic Ras proteins activate a network of downstream signalling pathways, including extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase (PI3K), promoting cell proliferation and survival. However, there is increasing evidence that RAS oncogenes also alter the mechanical properties of both individual malignant cells and transformed tissues. Here we discuss the role of oncogenic RAS in controlling mechanical cell phenotypes and how these mechanical changes promote oncogenic transformation in single cells and tissues. RAS activation alters actin organisation and actomyosin contractility. These changes alter cell rheology and impact mechanosensing through changes in substrate adhesion and YAP/TAZ-dependent mechanotransduction. We then discuss how these changes play out in cell collectives and epithelial tissues by driving large-scale tissue deformations and the expansion of malignant cells. Uncovering how RAS oncogenes alter cell mechanics will lead to a better understanding of the morphogenetic processes that underlie tumour formation in RAS-mutant cancers.
引用
收藏
页码:60 / 69
页数:10
相关论文
共 50 条
  • [41] THE RAS ONCOGENES IN HUMAN LUNG-CANCER
    RODENHUIS, S
    SLEBOS, RJC
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 142 (06): : S27 - S30
  • [42] FREQUENCY AND TYPE OF RAS ONCOGENES IN LYMPHOID MALIGNANCIES
    NERI, A
    BALDINI, L
    FERRERO, D
    MURPHY, JP
    KNOWLES, DM
    DALLAFAVERA, R
    MOLECULAR DIAGNOSTICS OF HUMAN CANCER, 1989, 7 : 101 - 105
  • [43] NORMAL AND ACTIVATED RAS ONCOGENES AND THEIR ENCODED PRODUCTS
    LEVINSON, AD
    TRENDS IN GENETICS, 1986, 2 (03) : 81 - 85
  • [44] Correction: RAS oncogenes: The first 30 years
    Marcos Malumbres
    Mariano Barbacid
    Nature Reviews Cancer, 2003, 3 (9) : 708 - 708
  • [45] MUTATIONAL ACTIVATION OF RAS ONCOGENES IN HUMAN HEPATOCARCINOGENESIS
    CHALLEN, C
    GUO, K
    CAVANAGH, D
    BASSENDINE, MF
    GUT, 1991, 32 (07) : A838 - A838
  • [46] Timeline - RAS oncogenes: the first 30 years
    Malumbres, M
    Barbacid, M
    NATURE REVIEWS CANCER, 2003, 3 (06) : 459 - 465
  • [47] HYPOMETHYLATION OF RAS ONCOGENES IN PRIMARY HUMAN CANCERS
    FEINBERG, AP
    VOGELSTEIN, B
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1983, 111 (01) : 47 - 54
  • [48] MicroRNAs: Modulators of the Ras Oncogenes in Oral Cancer
    Murugan, Avaniyapuram Kannan
    Munirajan, Arasambattu Kannan
    Alzahrani, Ali S.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2016, 231 (07) : 1424 - 1431
  • [49] THE EFFECT OF ONCOGENES H-RAS AND C-MYC ON THE RADIOSENSITIVITY OF A MINK EPITHELIAL-CELL LINE
    RUSSELL, J
    KERR, D
    BRITISH JOURNAL OF CANCER, 1990, 61 (01) : 173 - 173
  • [50] ACTIVATED RAS ONCOGENES IN HUMAN THYROID CANCERS
    LEMOINE, NR
    MAYALL, ES
    WYLLIE, FS
    FARR, CJ
    HUGHES, D
    PADUA, RA
    THURSTON, V
    WILLIAMS, ED
    WYNFORDTHOMAS, D
    CANCER RESEARCH, 1988, 48 (16) : 4459 - 4463